Hypothesis

Mitochondrial ROS in vascular smooth muscle cells (VSMCs) triggers the release of exosomes enriched in miRNA-21, which drives senescent cells to upregulate elastases and thereby amplifies elastin fragmentation, elastokine production, and arterial calcification.

Mechanistic Rationale

Oxidative modification of tropoelastin blocks elastic fiber assembly and promotes self‑aggregation [1]. Degradation by upregulated elastases from senescent cells generates elastokines such as VGVAPG that activate NEU1‑dependent inflammation and VSMC osteogenic transdifferentiation [2]. While antioxidants can reduce oxidative TE modifications [1] and senolytics lower elastase activity [2], the upstream signal that links mitochondrial ROS to elastase induction remains unclear. We propose that VSMC‑derived mitochondrial ROS activates the redox‑sensitive transcription factor NF‑κB p65, which increases transcription of the miRNA‑21 host gene (MIR21HG). miRNA‑21 is packaged into exosomes via the sphingomyelinase pathway and released into the extracellular milieu. Exosomal miRNA‑21 is taken up by neighboring senescent fibroblasts and macrophages, where it suppresses PTEN and PDCD4, leading to heightened AKT signaling and a SASP that includes MMP‑12 and cathepsin K—key elastases. This creates a feed‑forward loop: more ROS → more exosomal miRNA‑21 → more elastase → more elastin fragments → more elastokine‑driven inflammation → more VSMC ROS production via NOX activation. The loop explains why targeting only one node (e.g., senolytics) yields partial relief, whereas combined attenuation of mitochondrial ROS, exosomal release, and NEU1 signaling should break the cycle and permit elastic fiber reassembly.

Testable Predictions

1. In aged mice, VSMC‑specific overexpression of a mitochondria‑targeted catalase (mCAT) will reduce circulating exosomal miRNA-21 levels by >40% compared with controls.
2. Pharmacological inhibition of exosome release with GW4869 will decrease plasma elastokine concentrations and inhibit aortic calcification to a similar extent as dasatinib/quercetin treatment.
3. Simultaneous treatment with MitoQ (mitochondrial antioxidant), GW4869, and the NEU1 inhibitor DANA will restore elastin content in the aortic media (measured by histology and desmosine assay) to >80% of young adult levels, whereas each monotherapy will achieve <40% restoration.
4. Genetic deletion of MIR21HG in VSMCs will blunt elastase upregulation in senescent macrophages ex vivo and prevent elastokine‑induced IL‑6 release.

Experimental Design

Use 24‑month‑old C57BL/6 mice. Groups: (a) vehicle, (b) MitoQ, (c) GW4869, (d) DANA, (e) MitoQ+GW4869+DANA, (f) VSMC‑specific MIR21HG knockout, (g) VSMC‑mCAT transgenic. Monitor pulse wave velocity every 4 weeks for 12 weeks. At endpoint, quantify aortic elastin (Verhoeff‑Van Gieson staining, desmosine), circulating exosomes (NTA, miRNA‑21 qPCR), elastokines (ELISA for VGVAPG), calcification (von Kossa, calcium content), and inflammatory cytokines. Include young (3‑month) controls for baseline.

Potential Outcomes

If the hypothesis is correct, the combined MitoQ+GW4869+DANA group will show synergistic improvements in PWV, elastin content, and reduced calcification, exceeding additive effects of single agents. Conversely, if exosomal miRNA‑21 does not mediate elastase induction, GW4869 will fail to lower elastokines or calcification, falsifying the proposed mechanism.

All interventions are pharmacologically or genetically tractable, making the hypothesis readily falsifiable.